Home » Newsletters » BioWorld Science

BioWorld Science

March 26, 2018

View Archived Issues

Rheos Medicines launches with series A financing

Multivalent filovirus vaccines demonstrate immunogenicity and protection in nonhuman primates

European Commission approves Alofisel

EMA committee backs approval of Sandoz's biosimilar infliximab

New macrocyclic alpha-hydroxyphenylacetamide Mcl-1 inhibitor with in vivo efficacy against myeloma

Juluca receives positive opinion from EMA's CHMP

Cellivery investigates leptin-targeting antiobesity therapy

EMA committee issues negative opinion on Portola's betrixaban

First patient enrolled in phase III AEGIS-II study of CSL-112

VISTA protein identified as a biomarker and target in malignant pleural mesothelioma

Prevymis tablets and i.v. infusion approved in Japan

IMpower150 study of Tecentriq in NSCLC meets coprimary endpoint of overall survival

Phase IIb study of RPL-554 in COPD meets primary endpoint

Bayer Yakuhin receives Japanese approval of Sivextro

hVIVO reports initial results from phase IIb influenza challenge study of FLU-v

EMA recommends including new indication in Repatha label

European Commission grants orphan drug designation to ARGX-113 for myasthenia gravis

First-in-human data for KM-819 presented at ASCPT

Japanese authorities expand indication for Tafinlar and Mekinist combination therapy

IFM Therapeutics describes novel stimulator of interferon genes protein agonists

Shanghai Hansoh Biomedical, Jiangsu Hansoh Pharmaceutical Group patent CDK inhibitors

Amgen, Allergan receive positive opinion in E.U. for ABP-980

Novel thrombopoietin receptor agonists synthesized at Sichuan Kelun-Biotech Biopharmaceutical

Gachon University identifies novel AChE/NO production inhibitors

New indication, new formulation of Signifor LAR approved in Japan

Bristol-Myers Squibb discovers new Toll-like receptor 7, 8 and 9 antagonists

Lenvima approved in Japan for unresectable HCC

Peloton initiates phase II study of PT-2977 for VHL-associated renal cell carcinoma

Genentech develops anti-inflammatory nuclear receptor ROR-gamma inverse agonists

CHMP supports conditional marketing authorization for Clovis Oncology's Rubraca

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...